open access

Vol 52, No 2 (2018)
Original research articles
Submitted: 2017-09-01
Get Citation

Diagnostics, treatment and secondary prevention of ischemic stroke in the Silesian Province, Poland between 2009 and 2015

Beata Łabuz-Roszak, Anna Starostka-Tatar, Anetta Lasek-Bal, Marek Gierlotka, Mariusz Gąsior, Michał Skrzypek
DOI: 10.1016/j.pjnns.2017.11.003
·
Neurol Neurochir Pol 2018;52(2):235-242.

open access

Vol 52, No 2 (2018)
Original research articles
Submitted: 2017-09-01

Abstract

Background

The available data on diagnostics and treatment of ischemic stroke (IS) in Poland come mainly from non-representative cohorts or are outdated.

Objective

Therefore, the current study was done to access the most recent data on IS in the industrial region that covers 12% of the country's population.

Materials & methods

Analysis of the data from stroke questionnaires, obligatory for all patients hospitalized due to acute stroke and administered by the National Health Fund (the only public health insurer in Poland) between 2009 and 2015 (n=81,193).

Results

The number of hospitalizations due to IS in the Silesian Province was 69,403 and constituted 85.5% of all stroke cases reported to the NHF between 2009 and 2015. Neuroimaging of the brain (CT/MRI) was performed in 68,696 (99%) subjects, while ultrasonography of extra- and/or intracranial arteries in 57,886 (83.4%). The rtPA therapy was applied in 3282 patients (4.7% of all IS subjects). The rate of patients treated with rtPA gradually increased (1.2% in 2009, 9.3% in 2015). Among all patients with IS, 57,636 (83.1%) subjects were administered antiplatelet drugs, 16,199 (23.3%) – oral anticoagulants, and 55,971 (80.7%) – antihypertensive drugs. Also, 2260 (3.3%) patients were referred for vascular intervention. In subjects with cardioembolic stroke etiology, 37.8% were treated with anticoagulants.

Conclusions

There has been observed a significant improvement in the quality of diagnosis and treatment of acute ischemic stroke during recent years. However, further actions are required both in terms of reperfusion treatment (thrombolysis and/or thrombectomy) and secondary prevention of stroke.

Abstract

Background

The available data on diagnostics and treatment of ischemic stroke (IS) in Poland come mainly from non-representative cohorts or are outdated.

Objective

Therefore, the current study was done to access the most recent data on IS in the industrial region that covers 12% of the country's population.

Materials & methods

Analysis of the data from stroke questionnaires, obligatory for all patients hospitalized due to acute stroke and administered by the National Health Fund (the only public health insurer in Poland) between 2009 and 2015 (n=81,193).

Results

The number of hospitalizations due to IS in the Silesian Province was 69,403 and constituted 85.5% of all stroke cases reported to the NHF between 2009 and 2015. Neuroimaging of the brain (CT/MRI) was performed in 68,696 (99%) subjects, while ultrasonography of extra- and/or intracranial arteries in 57,886 (83.4%). The rtPA therapy was applied in 3282 patients (4.7% of all IS subjects). The rate of patients treated with rtPA gradually increased (1.2% in 2009, 9.3% in 2015). Among all patients with IS, 57,636 (83.1%) subjects were administered antiplatelet drugs, 16,199 (23.3%) – oral anticoagulants, and 55,971 (80.7%) – antihypertensive drugs. Also, 2260 (3.3%) patients were referred for vascular intervention. In subjects with cardioembolic stroke etiology, 37.8% were treated with anticoagulants.

Conclusions

There has been observed a significant improvement in the quality of diagnosis and treatment of acute ischemic stroke during recent years. However, further actions are required both in terms of reperfusion treatment (thrombolysis and/or thrombectomy) and secondary prevention of stroke.

Get Citation

Keywords

Ischemic stroke, Treatment, Diagnostics, Recombinant tissue plasminogen activator therapy, Secondary stroke prevention, Recombinant, Tissue plasminogen activator

About this article
Title

Diagnostics, treatment and secondary prevention of ischemic stroke in the Silesian Province, Poland between 2009 and 2015

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 52, No 2 (2018)

Pages

235-242

DOI

10.1016/j.pjnns.2017.11.003

Bibliographic record

Neurol Neurochir Pol 2018;52(2):235-242.

Keywords

Ischemic stroke
Treatment
Diagnostics
Recombinant tissue plasminogen activator therapy
Secondary stroke prevention
Recombinant
Tissue plasminogen activator

Authors

Beata Łabuz-Roszak
Anna Starostka-Tatar
Anetta Lasek-Bal
Marek Gierlotka
Mariusz Gąsior
Michał Skrzypek

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl